

Cont A1 Cont
6. (Amended) The pharmaceutical composition of claim 1, wherein the substance is a protein substance.

A2 Sub B4
8. (Amended) The pharmaceutical composition of claim 1, wherein the substance is a non-protein substance.

A3 Sub B4
13. (Amended) The pharmaceutical composition of claim 10, wherein the inflammation is hepatitis.

14. (Amended) The pharmaceutical composition of claim 10, wherein the substance is a protein substance.

A4 Sub B8
16. (Amended) The pharmaceutical composition of claim 10, wherein the substance is a non-protein substance.

A5 Sub B10
21. (Amended) The pharmaceutical composition of claim 18, wherein the substance is a protein substance.

A6 Sub B12
23. (Amended) The pharmaceutical composition of claim 18, wherein the substance is a non-protein substance.

A7 Sub B14
27. (Amended) The pharmaceutical composition of claim 25, wherein the substance has an activity in inhibiting proliferation of AILIM-expressing cells or in inhibiting production of a cytokine by AILIM-expressing cells.

A8 Sub B16
29. (Amended) The pharmaceutical composition of claim 25, wherein the substance is a protein substance.

A9 Sub B18
31. (Amended) The pharmaceutical composition of claim 25, wherein the substance is a non-protein substance.